查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1863427

癌症微生物定序市场：按技术、应用、工作流程、最终用户和样本类型划分－2025-2032年全球预测

Cancer Microbiome Sequencing Market by Technology, Application, Workflow, End User, Sample Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，癌症微生物定序市场将成长至 29.4 亿美元，复合年增长率为 6.04%。

关键市场统计数据
基准年 2024 18.4亿美元
预计年份：2025年 19.5亿美元
预测年份 2032 29.4亿美元
复合年增长率 (%) 6.04%

本书清晰、实用地说明了将微生物定序整合到癌症研究中如何改变研究设计、生物标记发现和转化途径。

分子生物学和定序技术的进步融合，开启了肿瘤学研究的新领域：阐明宿主相关微生物群落作为癌症生物学关键调控因子的作用。本执行摘要概述了癌症微生物组定序如何从单纯的探索性研究发展成为转化研究、临床试验优化和治疗创新的策略支柱。微生物组分析与肿瘤基因组学和免疫表型分析相结合，使研究人员和产业领袖能够发现机制关联，从而指导生物标记选择、患者分层和新型治疗标靶的识别。

以下页面整合了横断面研究证据和操作考量，涵盖技术选择、工作流程设计、法规遵循和商业性应用等面向。重点在于可重复性、分析灵敏度以及将定序结果转化为临床实用见解的解读框架。贯穿始终，专注于检测方法的可比性、样本处理限制以及将原始数据转化为可操作生物讯号所需的生物资讯方法。对于需要在科学目标和实际限制之间寻求平衡的决策者而言，本书旨在提供一个易于理解且严谨的基础，从而为从研究启动到临床应用的整个过程提供清晰的路径。

近年来，技术、计算和临床方面的进步正在重塑癌症微生物定序，使其朝着可重复性、临床相关性和实用化就绪性方向发展。

癌症微生物定序领域正经历着由技术成熟、计算能力提升和临床重点转变所驱动的多项变革。定序平台不断提高读长、通量和纠错能力，从而共同提升了分类解析度和功能推断能力。同时，强大的生物资讯流程和云端分析技术的兴起降低了从大型队列中提取多体学学相关性的门槛。这些进步使研究人员能够在严格控制污染和批次效应的同时，加快从假设生成到检验的整个过程。

同时，临床相关人员开始要求提供证据，证明微生物特征在不同人群中具有可重复性，并且能够预测治疗反应和不利事件等有意义的结局。这种需求正推动研究设计朝着纵向采样、标准化分析前通讯协定和统一的分析终点方向发展，从而提高研究结果的可重复性和临床可解释性。与监管机构的对话也在转变；重点正从微生物组数据能否为肿瘤学决策做出贡献，转向定义将微生物生物标记纳入治疗开发项目所需的证据标准和检验途径。这些变化正在塑造一个环境，​​在这个环境中，严谨且可重复的微生物组定序能够对临床试验设计和治疗策略产生重大影响。

评估美国关税政策的变化如何影响利用定序技术的肿瘤项目的采购、供应链韧性和营运规划

政策和贸易环境会影响高通量定序试剂、耗材和设备的成本结构和供应链韧性。 2025年，美国关税和海关政策的变化影响了采购时间表以及从全球供应商采购定序平台和试剂的相对经济效益。这些调整对实验室规划、设备采购和供应商选择流程产生了连锁反应，促使许多机构重新评估其供应商多元化策略和库存管理实践。

事实上，实验室和研究机构正在透过加强多供应商采购框架、协商长期供应协议以及增加关键耗材的本地库存缓衝来应对这一挑战。一些相关人员正在加速检验平台无关的工作流程并验证相容试剂，从而即使在面临暂时的进口中断时也能维持研究的发展。合约研究机构和学术核心设施也已开始製定紧急时应对计画研究并维持患者队列的长期连续性。总而言之，监管和关税的进展凸显了供应链韧性和策略采购在保障长期肿瘤学研究中定序操作的连续性和资料完整性方面的重要性。

定序技术、临床应用、工作流程组成部分、最终用户期望和检体特定因素与策略性研究设计连结起来的综合細項分析

对细分的深入理解对于制定研究设计和商业策略至关重要，这些策略应将技术、临床需求和营运能力相结合。本报告以技术为基础，探讨了16S rRNA定序、鸟枪法基因测序适用于经济高效的分类学研究；鸟枪法宏基因组定序能够实现物种层级的分辨率和功能基因检测；全基因测序则透过同时检验宿主和微生物基因组，提供全面的基因组背景资讯。这些差异将决定特定研究的深度、广度和解释范围。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 整合多体学和微生物组分析，用于生物标记发现和指南个人化癌症治疗
  • 人工智慧驱动的微生物组数据分析技术的进步提高了肿瘤微环境分析的准确性。
  • 非侵入性液态生物检体能够实现癌症的早期发现和监测。
  • 制定癌症微生物检体标准化通讯协定以提高可重复性
  • 透过加强生技公司与研究机构之间的合作，加速以微生物组为基础的药物研发
  • 不断发展的法规结构旨在应对微生物定序诊断核准和资料隐私方面的挑战
  • 利用16S rRNA进行鸟枪法宏基因体定序，以全面表征肿瘤相关微生物群

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依技术分類的癌症微生物定序市场

  • 16S rRNA定序
  • 鸟枪法宏基因组定序
  • 全基因组定序

9. 按应用分類的癌症微生物定序市场

  • 乳癌
  • 大肠直肠癌
  • 肺癌

10. 按工作流程分類的癌症微生物组定序市场

  • 分析
    • Illumina定序
    • 牛津奈米定序
    • Pacbio定序
  • 生物资讯学
    • 功能分析工具
    • 统计分析工具
    • 分类分析工具
  • 预分析

第十一章 依最终用户分類的癌症微生物定序市场

  • 医院和诊所
  • 製药和生物技术公司
  • 研究所

12. 依检体类型分類的癌症微生物组定序市场

  • 血液样本
  • 粪便样本
  • 组织样本

13. 各地区癌症微生物组定序市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 癌症微生物定序市场（按组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国癌症微生物定序市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Illumina, Inc.
    • Thermo Fisher Scientific, Inc.
    • Roche Holding AG
    • BGI Genomics Co., Ltd.
    • QIAGEN NV
    • Pacific Biosciences of California, Inc.
    • Oxford Nanopore Technologies Ltd.
    • Agilent Technologies, Inc.
    • Eurofins Scientific SE
    • Danaher Corporation
Product Code: MRR-5C6F41F5AF92

The Cancer Microbiome Sequencing Market is projected to grow by USD 2.94 billion at a CAGR of 6.04% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.84 billion
Estimated Year [2025] USD 1.95 billion
Forecast Year [2032] USD 2.94 billion
CAGR (%) 6.04%

A clear and actionable primer explaining why integrating microbiome sequencing into oncological research transforms study design, biomarker discovery, and translational pathways

Advances in molecular biology and sequencing technologies have converged to create a new frontier in oncology research: the interrogation of host-associated microbial communities as integral modulators of cancer biology. This executive summary frames why cancer microbiome sequencing has moved beyond exploratory curiosity to a strategic pillar for translational research, clinical trial enrichment, and therapeutic innovation. By situating microbial profiling alongside tumor genomics and immunophenotyping, investigators and industry leaders can uncover mechanistic links that inform biomarker selection, patient stratification, and novel therapeutic targets.

The following pages synthesize cross-cutting evidence and operational considerations for technology selection, workflow design, regulatory navigation, and commercial alignment. Emphasis is placed on reproducibility, analytical sensitivity, and interpretive frameworks that translate sequencing output into clinically relevant insight. Throughout, attention is paid to assay comparability, sample handling constraints, and the bioinformatics approaches needed to move from raw reads to actionable biological signals. The goal is to provide an accessible yet rigorous foundation for decision-makers who must balance scientific ambition with practical constraints, enabling clearer pathways from study inception to clinical utility.

How recent technological, computational, and clinical shifts are reshaping cancer microbiome sequencing toward reproducibility, clinical relevance, and translational readiness

The landscape of cancer microbiome sequencing is undergoing several transformative shifts driven by technological maturation, computational advances, and evolving clinical priorities. Sequencing platforms have increased read lengths, throughput, and error correction capacity, which together improve taxonomic resolution and functional inference. Concurrently, the rise of robust bioinformatics pipelines and cloud-enabled analytics has lowered barriers to extracting multi-omic correlations across large cohorts. These developments mean that researchers can move faster from hypothesis generation to hypothesis testing, while maintaining stringent controls for contamination and batch effects.

In parallel, clinical stakeholders are beginning to demand evidence that microbial signatures are repeatable across populations and predictive of meaningful outcomes such as therapy response or adverse events. This demand has pushed study designs toward longitudinal sampling, standardized pre-analytical protocols, and harmonized analytical endpoints so that findings are more readily reproducible and clinically interpretable. Regulatory conversations are also shifting: rather than debating whether microbiome data can inform oncology decision-making, attention is increasingly focused on defining the evidentiary standards and validation pathways required to embed microbial biomarkers within therapeutic development programs. Together, these shifts create an environment where rigorous, reproducible microbiome sequencing can materially influence clinical trial design and therapeutic strategy.

Assessment of how evolving tariff policies in the United States have reshaped procurement, supply chain resilience, and operational planning for sequencing-driven oncology programs

Policy and trade environments influence the cost structure and supply chain resilience for high-throughput sequencing reagents, consumables, and instruments. In 2025, tariff changes and customs policies in the United States have affected procurement timelines and the relative economics of sourcing sequencing platforms and reagents from global suppliers. These adjustments have had ripple effects across laboratory planning, capital procurement, and vendor selection processes, prompting many organizations to revisit supplier diversification strategies and inventory management practices.

Practically, laboratories and institutions have responded by strengthening multi-vendor purchasing frameworks, negotiating longer-term supply agreements, and increasing local inventory buffers for critical consumables. Some stakeholders have accelerated adoption of platform-agnostic workflows and validated interchangeable reagents so that studies can be maintained despite episodic import disruptions. Contract research organizations and academic core facilities have also begun to articulate contingency plans that prioritize key ongoing studies, preserving longitudinal continuity for patient cohorts. In sum, regulatory and tariff dynamics have underscored the importance of supply chain resilience and strategic procurement in sustaining uninterrupted sequencing operations and protecting data integrity across long-term oncology studies.

Comprehensive segmentation analysis linking sequencing technology, clinical application, workflow components, end-user expectations, and sample-specific considerations to strategic study design

A nuanced appreciation of segmentation is essential to design studies and commercial strategies that align technology, clinical need, and operational capacity. Based on Technology, the report examines comparative advantages and limitations of 16S rRNA sequencing, which remains valuable for cost-effective taxonomic surveys; shotgun metagenomic sequencing, which enables species-level resolution and functional gene detection; and whole genome sequencing, which offers comprehensive genomic context when host and microbial genomes are interrogated concurrently. These distinctions drive choices about depth, breadth, and interpretive scope for a given research question.

Based on Application, the work explores how different oncological contexts-Breast Cancer, Colorectal Cancer, and Lung Cancer-present unique opportunities and constraints for microbiome analysis. Tumor site, microenvironmental interactions, and clinical workflows influence sampling strategies and biomarker strategies, necessitating application-specific validation paths. Based on Workflow, emphasis is placed on the three interconnected stages of Pre Analytical, Analytical, and Bioinformatics. The Analytical domain is further evaluated across sequencing platforms including Illumina sequencing, Oxford Nanopore sequencing, and PacBio sequencing to elucidate trade-offs in read length, error profiles, and throughput. The Bioinformatics domain is further examined through the lens of Functional Analysis Tools that infer metabolic potential, Statistical Analysis Tools that support cohort-level inference, and Taxonomic Profiling Tools that recover community composition from sequencing data.

Based on End User, the analysis considers decision drivers for Hospitals And Clinics that require clinical-grade robustness, Pharmaceutical And Biotechnology Companies focused on biomarker qualification and companion diagnostic pathways, and Research Institutes that prioritize methodological innovation and mechanistic inquiry. Based on Sample Type, practical guidance is provided for blood samples that enable minimally invasive longitudinal monitoring, fecal samples that capture gut ecosystem dynamics, and tissue samples that preserve tumor microenvironment context. Integrating these segmentation lenses supports tailored study designs and commercialization approaches that account for technical constraints, regulatory expectations, and end-user needs.

Regional dynamics and infrastructure realities across the Americas, Europe, Middle East & Africa, and Asia-Pacific that determine translational pathways and collaborative opportunities

Regional dynamics shape scientific collaboration, regulatory expectations, and infrastructure preparedness in distinct ways. In the Americas, investments in sequencing infrastructure and translational oncology have matured alongside expanding networks of clinical trials and commercial diagnostic development, creating fertile ground for integrated microbiome-oncology initiatives. Access to centralized core facilities, clinical research organizations, and public-private partnerships accelerates the translation of microbial biomarkers into clinical test plans and therapeutic hypotheses.

In Europe, Middle East & Africa, the landscape is heterogeneous, with pockets of advanced genomic capacity in some countries and emerging capabilities in others. Regulatory harmonization efforts and pan-European consortia are enabling cross-border studies, but stakeholders must navigate variable reimbursement frameworks and ethical review processes. Capacity building and standardized protocols are key priorities to ensure that datasets from diverse geographies are comparable and clinically meaningful. In the Asia-Pacific region, rapid adoption of sequencing platforms, increasing clinical trial activity, and strong public sector investment in precision oncology are driving high-volume data generation. However, differences in sample logistics, data governance regimes, and local clinical practices necessitate careful operational planning to ensure cross-regional data interoperability and compliance with local regulations. Taken together, regional insights emphasize the need for adaptive study architectures that respect local constraints while enabling global evidence generation.

Insights into how platform innovators, reagent suppliers, bioinformatics firms, and clinical laboratories are collaborating and competing to deliver validated cancer microbiome sequencing solutions

The competitive and collaborative ecosystem around cancer microbiome sequencing includes platform manufacturers, reagent suppliers, bioinformatics companies, clinical laboratories, and translational research groups. Sequencing platform vendors have continued to innovate on throughput, accuracy, and ease of use, while reagent and consumable manufacturers focus on kit standardization and contamination control. Bioinformatics firms are differentiating through proprietary algorithms that enhance taxonomic resolution, functional annotation, and clinical-grade reporting, and clinical laboratories are building CLIA-equivalent workflows to support regulatory-compliant testing.

Strategic partnerships between instrument vendors and bioinformatics providers are enabling bundled solutions that reduce deployment friction for clinical and research customers. At the same time, collaborations among pharmaceutical companies, academic centers, and clinical networks are facilitating access to well-annotated cohorts for hypothesis-driven studies. New entrants are targeting niche opportunities such as targeted microbial gene panels or integrated host-microbiome pipelines for immune-oncology applications. For organizations planning alliances or vendor selections, the emphasis should be on compatibility with standardized protocols, demonstrated contamination control, and clear pathways for analytical validation and clinical interpretation. Ultimately, company strategies that prioritize interoperability and evidence generation will be better positioned to support reproducible, clinically relevant outcomes.

Actionable recommendations for industry leaders to strengthen protocols, diversify supply chains, and integrate analytics to deliver clinically credible microbiome-derived oncology insights

Industry leaders can translate the synthesis of technology, workflow, and regional insights into concrete actions that accelerate impact. First, prioritize validated pre-analytical protocols and contamination control measures as foundational investments; without reproducible sample handling, downstream analytical sophistication yields limited translational value. Next, adopt platform-agnostic analytical frameworks and cross-validate key findings across complementary sequencing technologies to reduce vendor lock-in and improve robustness. Integrate bioinformatics pipelines that combine taxonomic profiling with functional inference and statistical rigor to produce interpretable biomarkers that clinicians and regulators can evaluate.

Additionally, cultivate multi-stakeholder collaborations that pair clinical cohorts with laboratory capacity and advanced analytics, thereby shortening the path from discovery to clinical qualification. Strengthen supply chain resilience by diversifying vendors and negotiating contingency provisions for critical consumables. From an organizational perspective, invest in workforce development in both wet-lab best practices and computational genomics so that teams can manage end-to-end workflows. Finally, engage proactively with regulatory bodies and standards organizations to help shape practical validation pathways and clinical utility criteria that reflect the unique complexities of host-microbiome data.

A robust mixed-method research methodology combining expert interviews, protocol audits, and triangulated technical evidence to support reliable operational guidance

The research methodology underpinning this report blends primary qualitative engagement with systematic secondary synthesis to ensure both depth and credibility. Primary inputs include structured interviews with laboratory directors, bioinformatics leaders, clinical investigators, and regulatory advisors, providing first-hand perspectives on operational challenges and validation priorities. These interviews were complemented by protocol reviews and technical assessments of sequencing platforms and reagent systems to evaluate performance characteristics relevant to oncology-focused microbiome studies.

Secondary analysis incorporated peer-reviewed literature, regulatory guidance documents, and technical white papers to contextualize technological performance and clinical applications. Data triangulation was used to reconcile divergent viewpoints and to identify consensus best practices, with particular attention to pre-analytical variables, contamination controls, and bioinformatics reproducibility. Quality assurance processes included cross-validation of technical claims against independent protocol repositories and verification of analytical trade-offs through comparative platform assessments. Ethical and data governance considerations were examined to ensure recommendations respect patient privacy and jurisdictional compliance. Together, this mixed-method approach creates a transparent evidentiary basis for the report's operational and strategic guidance.

Concise synthesis highlighting why rigorous protocols, interoperable analytics, and collaborative evidence generation are essential to realize the translational promise of cancer microbiome sequencing

In conclusion, cancer microbiome sequencing stands at a pivotal moment where technical feasibility, computational maturity, and clinical need intersect to create tangible opportunities for translational impact. Achieving that potential requires disciplined attention to sample integrity, analytical comparability, and bioinformatics transparency. When these elements are aligned, microbial signals can complement tumor-centric information to inform patient stratification, predict therapeutic response, and reveal novel mechanistic targets.

Going forward, stakeholders should pursue harmonized protocols, invest in interoperable analytics, and foster collaborative networks that enable robust, reproducible studies across geographies and clinical contexts. With careful operational planning and a focus on evidence generation, the integration of microbiome sequencing into oncology programs can advance both scientific understanding and patient-centered outcomes, laying the groundwork for durable translational success.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of multi-omics microbiome sequencing for personalized cancer therapy guidance and biomarker discovery
  • 5.2. Advances in AI-driven microbiome data analytics enhancing tumor microenvironment profiling accuracy
  • 5.3. Emergence of non-invasive liquid biopsy microbiome assays for early cancer detection and monitoring
  • 5.4. Development of standardized protocols for cancer microbiome sample collection to improve reproducibility
  • 5.5. Growth of partnerships between biotech firms and research institutes to accelerate microbiome-based drug development
  • 5.6. Regulatory frameworks evolving to address microbiome sequencing diagnostic approvals and data privacy challenges
  • 5.7. Adoption of shotgun metagenomic sequencing over 16S rRNA for comprehensive tumor-associated microbiota characterization

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Microbiome Sequencing Market, by Technology

  • 8.1. 16S Rrna Sequencing
  • 8.2. Shotgun Metagenomic Sequencing
  • 8.3. Whole Genome Sequencing

9. Cancer Microbiome Sequencing Market, by Application

  • 9.1. Breast Cancer
  • 9.2. Colorectal Cancer
  • 9.3. Lung Cancer

10. Cancer Microbiome Sequencing Market, by Workflow

  • 10.1. Analytical
    • 10.1.1. Illumina Sequencing
    • 10.1.2. Oxford Nanopore Sequencing
    • 10.1.3. Pacbio Sequencing
  • 10.2. Bioinformatics
    • 10.2.1. Functional Analysis Tools
    • 10.2.2. Statistical Analysis Tools
    • 10.2.3. Taxonomic Profiling Tools
  • 10.3. Pre Analytical

11. Cancer Microbiome Sequencing Market, by End User

  • 11.1. Hospitals And Clinics
  • 11.2. Pharmaceutical And Biotechnology Companies
  • 11.3. Research Institutes

12. Cancer Microbiome Sequencing Market, by Sample Type

  • 12.1. Blood Samples
  • 12.2. Fecal Samples
  • 12.3. Tissue Samples

13. Cancer Microbiome Sequencing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cancer Microbiome Sequencing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cancer Microbiome Sequencing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Illumina, Inc.
    • 16.3.2. Thermo Fisher Scientific, Inc.
    • 16.3.3. Roche Holding AG
    • 16.3.4. BGI Genomics Co., Ltd.
    • 16.3.5. QIAGEN N.V.
    • 16.3.6. Pacific Biosciences of California, Inc.
    • 16.3.7. Oxford Nanopore Technologies Ltd.
    • 16.3.8. Agilent Technologies, Inc.
    • 16.3.9. Eurofins Scientific SE
    • 16.3.10. Danaher Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WORKFLOW, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WORKFLOW, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. CANCER MICROBIOME SEQUENCING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. CANCER MICROBIOME SEQUENCING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CANCER MICROBIOME SEQUENCING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY 16S RRNA SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY 16S RRNA SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY 16S RRNA SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY 16S RRNA SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY 16S RRNA SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY 16S RRNA SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SHOTGUN METAGENOMIC SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SHOTGUN METAGENOMIC SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SHOTGUN METAGENOMIC SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SHOTGUN METAGENOMIC SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SHOTGUN METAGENOMIC SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SHOTGUN METAGENOMIC SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ANALYTICAL, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ANALYTICAL, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ANALYTICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ANALYTICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ANALYTICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ANALYTICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ANALYTICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ANALYTICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ILLUMINA SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ILLUMINA SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ILLUMINA SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ILLUMINA SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ILLUMINA SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ILLUMINA SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY OXFORD NANOPORE SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY OXFORD NANOPORE SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY OXFORD NANOPORE SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY OXFORD NANOPORE SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY OXFORD NANOPORE SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY OXFORD NANOPORE SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PACBIO SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PACBIO SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PACBIO SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PACBIO SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PACBIO SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PACBIO SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BIOINFORMATICS, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BIOINFORMATICS, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BIOINFORMATICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BIOINFORMATICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BIOINFORMATICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BIOINFORMATICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY FUNCTIONAL ANALYSIS TOOLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY FUNCTIONAL ANALYSIS TOOLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY FUNCTIONAL ANALYSIS TOOLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY FUNCTIONAL ANALYSIS TOOLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY FUNCTIONAL ANALYSIS TOOLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY FUNCTIONAL ANALYSIS TOOLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY STATISTICAL ANALYSIS TOOLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY STATISTICAL ANALYSIS TOOLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY STATISTICAL ANALYSIS TOOLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY STATISTICAL ANALYSIS TOOLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY STATISTICAL ANALYSIS TOOLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY STATISTICAL ANALYSIS TOOLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TAXONOMIC PROFILING TOOLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TAXONOMIC PROFILING TOOLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TAXONOMIC PROFILING TOOLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TAXONOMIC PROFILING TOOLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TAXONOMIC PROFILING TOOLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TAXONOMIC PROFILING TOOLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRE ANALYTICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRE ANALYTICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRE ANALYTICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRE ANALYTICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRE ANALYTICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRE ANALYTICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BLOOD SAMPLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BLOOD SAMPLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BLOOD SAMPLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BLOOD SAMPLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BLOOD SAMPLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BLOOD SAMPLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY FECAL SAMPLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY FECAL SAMPLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY FECAL SAMPLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY FECAL SAMPLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY FECAL SAMPLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY FECAL SAMPLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TISSUE SAMPLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TISSUE SAMPLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TISSUE SAMPLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TISSUE SAMPLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TISSUE SAMPLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TISSUE SAMPLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ANALYTICAL, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ANALYTICAL, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BIOINFORMATICS, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BIOINFORMATICS, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ANALYTICAL, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ANALYTICAL, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BIOINFORMATICS, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BIOINFORMATICS, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ANALYTICAL, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ANALYTICAL, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BIOINFORMATICS, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BIOINFORMATICS, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ANALYTICAL, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ANALYTICAL, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BIOINFORMATICS, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BIOINFORMATICS, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ANALYTICAL, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ANALYTICAL, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BIOINFORMATICS, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BIOINFORMATICS, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 230. MIDDLE EAST CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 232. MIDDLE EAST CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ANALYTICAL, 2018-2024 (USD MILLION)
  • TABLE 236. MIDDLE EAST CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ANALYTICAL, 2025-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BIOINFORMATICS, 2018-2024 (USD MILLION)
  • TABLE 238. MIDDLE EAST CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BIOINFORMATICS, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 246. AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 247. AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 248. AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 249. AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 250. AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 251. AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ANALYTICAL, 2018-2024 (USD MILLION)
  • TABLE 252. AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ANALYTICAL, 2025-2032 (USD MILLION)
  • TABLE 253. AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BIOINFORMATICS, 2018-2024 (USD MILLION)
  • TABLE 254. AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BIOINFORMATICS, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ANALYTICAL, 2018-2024 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ANALYTICAL, 2025-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BIOINFORMATICS, 2018-2024 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BIOINFORMATICS, 2025-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. ASEAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. ASEAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. ASEAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 280. ASEAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 281. ASEAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 282. ASEAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 283. ASEAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 284. ASEAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 285. ASEAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ANALYTICAL, 2018-2024 (USD MILLION)
  • TABLE 286. ASEAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ANALYTICAL, 2025-2032 (USD MILLION)
  • TABLE 287. ASEAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BIOINFORMATICS, 2018-2024 (USD MILLION)
  • TABLE 288. ASEAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BIOINFORMATICS, 2025-2032 (USD MILLION)
  • TABLE 289. ASEAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 290. ASEAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 291. ASEAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. ASEAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. GCC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. GCC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. GCC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 296. GCC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 297. GCC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 298. GCC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 299. GCC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 300. GCC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WOR